SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-203902
Filing Date
2023-08-04
Accepted
2023-08-04 16:21:36
Documents
13
Period of Report
2023-07-31
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d416994d8k.htm   iXBRL 8-K 27386
2 EX-16.1 d416994dex161.htm EX-16.1 1793
  Complete submission text file 0001193125-23-203902.txt   152064

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20230731.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20230731_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20230731_pre.xml EX-101.PRE 11267
7 EXTRACTED XBRL INSTANCE DOCUMENT d416994d8k_htm.xml XML 3343
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 231144319
SIC: 2834 Pharmaceutical Preparations